Beyond long-standing dietary and vitamin-based management, recent developments include enzyme replacement therapy programs, pharmacological chaperone approaches designed to stabilize the CBS enzyme, and early-stage gene therapy candidates with one prior program (pegtarviliase) discontinued and succeeded by a newer candidate (rebranded SYNT-202) still progressing through development
This review evaluates the current available evidence for GLP-1 receptor agonists, dual GLP-1/GIP receptor co-agonists with a focus on GLP-1/GIP/glucagon receptor triagonists and discusses the potential future benefits and research directions
Asawanonda, P
These brands are popular in aesthetic clinics and offer a good balance of perceived quality and cost, making them excellent choices for those looking for effective results without the top-tier investment, provided they are sourced genuinely and administered correctly
(10) Engel MG, Narayan S, Cui MH, Branch CA, Zhang X, Gandy SE, Ehrlich M, Huffman DM
